International Journal of Bifurcation and Chaos.
World Scientific Publishing Co. Pte Ltd.
Vol. 30.
2020.
Non-coding RNA and immune-checkpoint inhibitors: Friends or foes?
Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. Immune-checkpoint inhibitors (ICIs) are considered one of the most promising and highly effective therapeutic approaches for cancer treatment. ICIs are monoclonal antibodies targeting immune checkpoints such as CTLA-4, PD-1 and PD-L1 signalling pathways that stimulate T cell cytotoxicity and can result in tumor growth suppression. This Review will summarize existing knowledge regarding ncRNAs and their role in cancer and ICI therapy. In addition, we will discuss potential mechanisms by which ncRNAs may influence ICI treatment outcomes. © 2020 Future Medicine Ltd.
Authors
Journal
Publisher
Future Medicine Ltd.
Number of issue
7
Language
English
Pages
513-529
Status
Published
Link
Volume
12
Year
2020
Organizations
- 1 Blacktown Clinical School and Research Centre, Western Sydney University, Sydney, NSW, Australia
- 2 Accreditation Centre, RUDN University, Moscow, Russian Federation
- 3 Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia
- 4 Westmead Hospital and Westmead Clinical School, University of Sydney, Sydney, NSW, Australia
- 5 Melanoma Institute Australia, Sydney, NSW, Australia
- 6 Blacktown Hospital, Sydney, NSW, Australia
Keywords
anticancer monoclonal antibodies; cancer immunotherapy; CTLA-4; immune checkpoints; immune-checkpoint inhibitors; long non-coding RNA; microRNA; non-coding RNA; PD-1; PD-L1
Share
Other records
Computer Physics Communications.
Elsevier Science Publishers B.V., Amsterdam.
Vol. 250.
2020.